Cargando…
ARHGEF15 overexpression worsens the prognosis in patients with pancreatic ductal adenocarcinoma through enhancing the motility and proliferative activity of the cancer cells
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive neoplastic diseases, associated with a remarkably poor prognosis. However, the molecular mechanisms underlying the development of PDAC remain elusive. The aim of this study was to identify genes whose expressions are c...
Autores principales: | Fukushima, Hiroto, Yasumoto, Makiko, Ogasawara, Sachiko, Akiba, Jun, Kitasato, Yuhei, Nakayama, Masamichi, Naito, Yoshiki, Ishida, Yusuke, Okabe, Yoshinobu, Yasunaga, Masafumi, Horiuchi, Hiroyuki, Sakamoto, Etsuko, Itadani, Hiraku, Mizuarai, Shinji, Oie, Shinji, Yano, Hirohisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4857279/ https://www.ncbi.nlm.nih.gov/pubmed/27145964 http://dx.doi.org/10.1186/s12943-016-0516-4 |
Ejemplares similares
-
Muscle RAS oncogene homolog (MRAS) recurrent mutation in Borrmann type IV gastric cancer
por: Yasumoto, Makiko, et al.
Publicado: (2016) -
Can Systems Biology Understand Pathway Activation? Gene Expression Signatures as Surrogate Markers for Understanding the Complexity of Pathway Activation
por: Itadani, Hiraku, et al.
Publicado: (2008) -
3'-Ethynylcytidine, an RNA polymerase inhibitor, combined with cisplatin exhibits a potent synergistic growth-inhibitory effect via Vaults dysfunction
por: Fukushima, Hiroto, et al.
Publicado: (2014) -
Expression ratio of CCND1 to CDKN2A mRNA predicts RB1 status of cultured cancer cell lines and clinical tumor samples
por: Mizuarai, Shinji, et al.
Publicado: (2011) -
Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor
por: Mizuarai, Shinji, et al.
Publicado: (2009)